Boron neutron capture therapy for head and neck cancer: Relevance of nuclear-cytoplasmic volume ratio and anti-tumor effect. -A preliminary report.


Journal

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
ISSN: 1872-9800
Titre abrégé: Appl Radiat Isot
Pays: England
ID NLM: 9306253

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 05 08 2019
revised: 23 03 2020
accepted: 29 04 2020
entrez: 21 6 2020
pubmed: 21 6 2020
medline: 11 8 2021
Statut: ppublish

Résumé

BNCT is a type of particle beam radiation therapy that utilizes an α particle and 7Li nucleus generated when a thermal neutron is captured by a 10B nucleus involved in the boron compound that has been taken up into tumor tissue selectively. In this report, the relevance of N/C ratio of tumor cell and anti-tumor effect for BNCT clinical cases of head and neck cancer were verified. Examination of pre-irradiated tumor histopathological specimens of 9 BNCT treated head and neck cancer patients (4 CR patients, 5 non-CR patients) was performed. The statistically significant difference between the CR group and the non-CR group was examined for the physical dose was multiplied by the absolute biological effectiveness (ABE) value determined from the patient's tumor specific N/C ratio. Analysis showed the mean tumor dose could not distinguish between CR and non-CR groups. However, the ABE dose could clearly distinguish between the CR group and the non-CR group (p = 0.0250). The N/C ratio of tumor cell can influence the anti-tumor effect of BNCT for HNC.

Identifiants

pubmed: 32561048
pii: S0969-8043(20)30341-9
doi: 10.1016/j.apradiso.2020.109212
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109212

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None to declare. Kawasaki Medical School IRB approval number 40, 110.

Auteurs

Teruhito Aihara (T)

Kansai BNCT Medical Center and Department of Otolaryngology Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan; Department of Otolaryngology Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan. Electronic address: taihara@osaka-med.ac.jp.

Junichi Hiratsuka (J)

Departments of Radiation Oncology and Departments of Pathology, Kawasaki Medical School, Kurashiki, Japan.

Nobuhiko Kamitani (N)

Departments of Radiation Oncology and Departments of Pathology, Kawasaki Medical School, Kurashiki, Japan.

Hirotake Nishimura (H)

Departments of Pathology, Kawasaki Medical School, Kurashiki, Japan.

Koji Ono (K)

Kansai BNCT Medical Center and Department of Otolaryngology Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH